Vasomotor Effects of Dimethyl Sulfoxide on Cat Cerebral Arteries In Vitro and In Vivo

L.H. Pitts, M.D.,* A.R. Young Ph.D.,† J. McCulloch, Ph.D.,‡ and E. MacKenzie, Ph.D.

SUMMARY We studied the direct vascular effects of dimethyl sulfoxide (DMSO) in isolated middle cerebral arteries and on pial arteriolar caliber after subarachnoid perivascular microinjection in chloralose-anesthetized cats, and on brain retraction in cats given DMSO intravenously. DMSO did not constrict isolated cerebral arteries at any of the concentrations studied (10^{-10} to 4 \times 10^{-1} M). In middle cerebral arteries precontracted with potassium, 5-hydroxytryptamine, prostaglandin F_{2alpha}, or with mechanically raised tone, DMSO at concentrations of 10^{-10} to 10^{-2} M had no significant effects; at concentrations greater than 10^{-2} M, DMSO consistently relaxed the arteries, probably because of the hyperosmolarity of the bathing solution. Microapplication of DMSO (10^{-10} to 10^{-2} M) around pial arterioles on the cortical surface did not change arteriolar caliber significantly. Higher concentrations of DMSO (1%) increased arteriolar caliber by 56 ± 4% (p < 0.001), probably as a consequence of solution hypertonicity. DMSO did not modify in vivo cerebrovascular responses to alterations in perivascular potassium ion concentrations. Intravenous administration of DMSO did cause obvious brain shrinkage. These data provide no support for the view that direct cerebral vascular effects play a major role in the clinical efficacy of DMSO, but are consistent with the hypothesis that DMSO’s ability to lower intracranial pressure derives from its osmotic effect on cerebral tissue.

DIMETHYL SULFOXIDE (DMSO) has been reported to reduce morbidity and mortality in some 1-2 but not other studies 3 4 of cerebral infarction, pressure-induced ischemia, 5 and trauma, 6 7 and to lower traumatic intracranial hypertension and improve cerebral perfusion in humans 8 9 and animals. 7 10 11 In our current clinical trial of the effect of DMSO on raised intracranial pressure (ICP) after severe head injury, ICP was lowered within minutes after intravenous (IV) administration of DMSO in some patients (unpublished data). The mechanism of action of DMSO is unknown, although hypertonicity and direct cerebrovascular effects are two possible hypotheses. In this study, we investigated both the direct vasomotor effects of DMSO on isolated feline middle cerebral arteries in vitro and alterations resulting from microapplication of DMSO around individual pial arterioles on the cortical surface of anesthetized cats.

Materials and Methods

Response to Middle Cerebral Pial Arteries In Vitro

These experiments were conducted using techniques described previously. 12 Six cats were anesthetized with 5% halothane, exsanguinated, and decapitated. The middle cerebral arteries were dissected and placed in cold Krebs'-Ringer's buffer solution (composition in mM: NaCl, 118; KCl, 4.5; Mg SO_{4} \cdot 2H_{2}O, 1.0; KH_{2}PO_{4}, 1.0; NaHCO_{3}, 25.0; CaCl_{2} \cdot 2H_{2}O, 2.5; glucose, 6.0). Sections of artery 5 to 6 mm long were mounted on two L-shaped metal holders, one of which was attached to a force-displacement transducer to allow attachment to two L-shaped metal holders, one of which was attached to a force-displacement transducer to allow attachment of the vessel to the cortical surface of anesthetized cats.

From the Department of Neurological Surgery, School of Medicine, University of California, San Francisco, California;* Department of Biology, Laboratoires d’Etudes et de Recherches Synthelabo, Bagneux, France; † and Wellcome Surgical Institute, University of Glasgow, Glasgow, Scotland. * This research was supported in part by NINCDS grants 5 K07 NS00436 and NS14543 and by Research Industries Corporation. Address correspondence to: Lawrence H. Pitts, M.D., c/o The Editorial Office, Department of Neurological Surgery, 1360 Ninth Avenue, Suite 210, San Francisco, California 94122.

Received February 27, 1985; revision #2 accepted September 30, 1985.
infusion of alphaxalone, 9 mg/kg, and alphadalone, 3 mg/kg (Saffan, Glaxovet Ltd., Middlesex, England), intubated, and ventilated by intermittent positive pressure with a 33% N2O/67% O2 mixture. Anesthesia was maintained by periodic IV infusion of a 1% alphachloralose solution. Exhaled gases were monitored continuously with an infrared CO2 analyzer; arterial PO2, PCO2, and pH were measured periodically so they could be maintained within a physiologic range (PO2 = 172 ± 28 torr; PCO2 = 30 ± 2 torr; pH = 7.34 ± 0.04). The head of the cat was placed in a stereotactic frame, and a 2 x 3-cm left parietal craniotomy was made with a dental drill under continuous saline irrigation. The dura was covered with a 1.5 cm layer of circulating mineral oil (38°C) and then opened under magnification (Bausch & Lomb stereomicroscope with zoom lens) and cold lighting from fiberoptic sources (Schott). Arteriolar calibers were measured by a standard image-splitting technique.

Shortly before use, DMSO (Rimso, Research Industries, Salt Lake City, Utah) was dissolved to various concentrations (0.0001% to 1%) in normokalemic mock cerebrospinal fluid (CSF) (composition in mM: Na+, 156; K+, 3; Ca++, 2.5; HCO3-, 12; Cl-, 152) or mock CSF with 10-mM K+ (Na+, 149; K+, 10; Ca++, HCO3-, Cl-, unchanged) or 40-mM K+ (Na+, 129; K+, 40; Ca++, HCO3-, Cl-, unchanged). One percent DMSO was prepared by diluting 1 ml of pure DMSO (1.1 g) to 100 ml by addition of mock CSF. All solutions were adjusted to pH 7.2 by aeration with 5% CO2/95% O2 and aspirated under a thin film of mineral oil into glass micropipettes with tip diameters of 8 to 10 μm.

One series of injections was made with mock CSF containing increased NaCl (composition in mM: Na+, 224; K+, 3; Ca++, 2.5, HCO3-, 12; Cl-, 220) to produce a total solution osmolarity similar to that of artificial CSF, DMSO in mock CSF.

A micromanipulator was used to place the micropipettes into the subarachnoid space near a pial vessel. A minute amount (about 5 μl) of solution was injected over 10 to 15 seconds; changes in vessel diameter were measured during the next 3 to 6 minutes, by which time the vessels had returned to control diameters. Alterations were expressed as the percent change from the injection diameter and compared by analysis of variance with those induced by injection of mock CSF.

Intravenous Infusion of DMSO

To evaluate the effect of DMSO on arterial pressure and brain size, DMSO (1 g/kg in a 10% solution) was infused intravenously in 2 cats. A blunt metal probe was positioned perpendicular to and gently on the brain and periodically adjusted to document changes in the position of the brain surface. At the end of the 1-hour infusion, a second dose of DMSO (1 g/kg in a 20% solution) was given over 3 to 5 minutes. Changes in blood pressure and brain surface location were noted.

Results

Middle Cerebral Arteries in Vitro

At concentrations of 10^-5 to 10^-2 M, DMSO had little effect on the tone generated by middle cerebral arteries (n = 6) in vitro, although it produced slight relaxation at higher concentrations (10^-2 to 4 x 10^-1 M) (fig. 1). In vessels constricted with PGF2α (620 ± 100 dyne; n = 11), DMSO resulted in vasodilatation equivalent to 85% of the induced tone, but only at the highest concentrations studied. The EC50 was 1.08 ± 0.35 x 10^-1 M and the EAm was −490 ± 70 dyne. 5-HT caused cerebral artery constriction amounting to 890 ± 150 dyne (n = 7). The subsequent cumulative addition of DMSO resulted in vasodilatation equal to 60% of the induced tone; again, this effect occurred only at the highest concentrations. The EC50 was 0.94 ± 0.70 x 10^-1 M and the EAm was not different from that in vessels constricted with PGF2α (−510 ± 70 dyne). The buffer solution containing 127 mM potassium provoked maximal vasoconstriction of the cerebral vessels (50 ± 300 dyne; n = 13). Once again, DMSO relaxed middle cerebral arteries, but only in high concentrations (>10^-2 M); the amount of relaxation (13% of the induced tone) was somewhat less than in arteries preconstricted with PGF2α or 5-HT. However, the EC50 value was similar to that described above (1.56 ± 0.36 x 10^-1 M), and the EAm was −230 ± 50 dyne.

Pial Arterioles in Vivo

Perivascular microinjections of artificial CSF had little effect on pial arteriolar caliber (mean response, 1.5 ± 2.4%; n = 18). In artificial CSF, DMSO in concentrations of 0.0001% to 0.5% produced no significant effect on arteriolar caliber, although at high concentrations (e.g., 1%), arteriolar caliber was increased significantly (fig. 2). Neither the cerebrovascular dilatations provoked by microinjections of moderately elevated potassium concentrations (10 mM) nor the constrictions provoked by microinjections of markedly elevated potassium concentrations (40 mM)
were modified by the presence of DMSO (0.1%, or $10^{-2}$ M) in the injectate (fig. 3).

**Osmolar Effects**

The mean osmolarity of the Krebs' solution — 285 mosmol/l, determined by freezing point depression — was not altered by DMSO in concentrations of $10^{-4}$ to $10^{-2}$ M, but it was increased significantly by concentrations greater than $10^{-2}$ M (fig. 4). This change in osmolarity correlated extremely well with the concentration at which vasodilatation was first observed in the cerebral vessels.

The presence of DMSO in concentrations less than 0.01% had no effect on the osmolarity of the mock CSF, but higher concentrations produced concentration-dependent increases in osmolarity (e.g., artificial CSF: 299 ± 4 mosmol; DMSO 1%: 486 ± 5 mosmol). To determine the contribution of hypertonicity to the vascular effects of DMSO in vivo, hypertonic solutions of CSF (454 mosmol) produced by increasing the NaCl concentration were administered perivascularly.

**Arteriolar Responses to Potassium**

Intravenous Infusion of DMSO

After the last perivascular microinjection in 2 cats early in the series, intravenous infusion of 10% DMSO (1 g/kg) caused the brain to shrink visibly and recede from the edge of the dura. Later, in another 2 cats, we measured the changes in brain surface location and mean arterial pressure (MAP) during infusion of DMSO. In the first cat, the brain retracted 0.7 mm within 15 minutes after the start of the infusion (0.25 g/kg DMSO delivered) and remained retracted even though blood pressure rose from 75 to 100 mm Hg. Within 2 minutes after a second dose of DMSO, given more rapidly, MAP rose from 75 to 138 mm Hg, and was accompanied by a slight transient increase in brain size (maximal retraction, 0.4 mm). Ten minutes after the second injection, the brain retracted further, to a maximum of 1.9 mm, despite continuing hypertension (MAP = 110 mm Hg). In the second cat, the brain retracted 1.1 mm within 10 minutes after the start of the infusion (0.16 g/kg DMSO delivered), and remained retracted even though blood pressure rose from 75 to 100 mm Hg. Within 2 minutes after a second dose of DMSO, given more rapidly, MAP rose from 75 to 138 mm Hg, and was accompanied by a slight transient increase in brain size (maximal retraction, 0.4 mm). Ten minutes after the second injection, the brain retracted further, to a maximum of 1.9 mm, despite continuing hypertension (MAP = 110 mm Hg). In the second cat, the brain retracted 1.1 mm within 10 minutes after the start of the infusion (0.16 g/kg DMSO delivered), even though MAP increased from 112 to 127 mm Hg. At 1 hour, retraction was 2.1 mm despite hypertension to 160 mm Hg. The second DMSO injection further retracted the brain to a maximum of 2.9 mm when the MAP was 125 mm Hg. Postinjection hypertension to 190 mm Hg caused a slight increase in brain size, but even then the brain surface was 1.2 mm below its preinfusion position.
blood volume, which would argue against decreased cerebral blood volume as the cause of brain shrinkage in our experiments. The time course of brain surface retraction was similar to that reported for ICP reduction from both DMSO and urea in monkeys and in our preliminary studies in humans.

The possibility that the cerebrovascular responses of the cat differ substantially from those of man cannot be absolutely excluded, but it seems highly unlikely. The responses of human and feline cerebral arteries to a wide variety of agents, including noradrenaline, serotonin, histamine, prostaglandins, neuronal polypeptides, and calcium antagonists, are qualitatively and quantitatively similar. Nor does DMSO show striking interspecies differences in toxicity. Thus, the results of these studies in cats probably apply to DMSO use in humans.

In conclusion, DMSO exerted no direct vascular effect that would contribute to its ability to lower ICP, although cerebrovascular dilatation consistent with an osmotic effect occurred at high concentrations of the drug that would be unlikely to occur clinically. Nonetheless, systemic administration of DMSO in cats produced brain shrinkage, which is consistent with its reported ability to lower ICP. These observations emphasize the need for further investigation of the mechanisms of action of DMSO, but its lack of potentially deleterious actions on the cerebral vasculature and its ability to lower ICP justify continued use of DMSO in rigorously controlled studies of human head injury.

Acknowledgments
The authors thank Tania Retivov for manuscript preparation and Stephen Ordway for editorial assistance.

References
11. Tsuruda J, James HE, Camp PE, Werner R: Acute dimethyl sulfox-
Intravenous dimethyl sulfoxide in cats. Pitts et al.

Vasomotor effects of dimethyl sulfoxide on cat cerebral arteries in vitro and in vivo.
L H Pitts, A R Young, J McCulloch and E MacKenzie

Stroke. 1986;17:483-487
doi: 10.1161/01.STR.17.3.483

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1986 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/17/3/483

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/